Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
4-Oxospiro[benzopyran-2,4'-piperidines] as class III antiarrhythmic agents. Pharmacological studies on 3,4-dihydro-1'-[2-(benzofurazan-5-yl)- ethyl]-6-methanesulfonamidospiro[(2H)-1-benzopyran-2,4'-piperidin]-4-on e (L-691,121).
Elliott JM, Selnick HG, Claremon DA, Baldwin JJ, Buhrow SA, Butcher JW, Habecker CN, King SW, Lynch JJ Jr, Phillips BT, et al. Elliott JM, et al. Among authors: selnick hg. J Med Chem. 1992 Oct 16;35(21):3973-6. doi: 10.1021/jm00099a028. J Med Chem. 1992. PMID: 1433205 No abstract available.
Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.
Liverton NJ, Butcher JW, Claiborne CF, Claremon DA, Libby BE, Nguyen KT, Pitzenberger SM, Selnick HG, Smith GR, Tebben A, Vacca JP, Varga SL, Agarwal L, Dancheck K, Forsyth AJ, Fletcher DS, Frantz B, Hanlon WA, Harper CF, Hofsess SJ, Kostura M, Lin J, Luell S, O'Neill EA, O'Keefe SJ, et al. Liverton NJ, et al. Among authors: selnick hg. J Med Chem. 1999 Jun 17;42(12):2180-90. doi: 10.1021/jm9805236. J Med Chem. 1999. PMID: 10377223
In vitro and in vivo evaluation of dihydropyrimidinone C-5 amides as potent and selective alpha(1A) receptor antagonists for the treatment of benign prostatic hyperplasia.
Barrow JC, Nantermet PG, Selnick HG, Glass KL, Rittle KE, Gilbert KF, Steele TG, Homnick CF, Freidinger RM, Ransom RW, Kling P, Reiss D, Broten TP, Schorn TW, Chang RS, O'Malley SS, Olah TV, Ellis JD, Barrish A, Kassahun K, Leppert P, Nagarathnam D, Forray C. Barrow JC, et al. Among authors: selnick hg. J Med Chem. 2000 Jul 13;43(14):2703-18. doi: 10.1021/jm990612y. J Med Chem. 2000. PMID: 10893308
Discovery and initial structure-activity relationships of trisubstituted ureas as thrombin receptor (PAR-1) antagonists.
Barrow JC, Nantermet PG, Selnick HG, Glass KL, Ngo PL, Young MB, Pellicore JM, Breslin MJ, Hutchinson JH, Freidinger RM, Condra C, Karczewski J, Bednar RA, Gaul SL, Stern A, Gould R, Connolly TM. Barrow JC, et al. Among authors: selnick hg. Bioorg Med Chem Lett. 2001 Oct 22;11(20):2691-6. doi: 10.1016/s0960-894x(01)00538-8. Bioorg Med Chem Lett. 2001. PMID: 11591503
Pharmacokinetic optimization of 3-amino-6-chloropyrazinone acetamide thrombin inhibitors. Implementation of P3 pyridine N-oxides to deliver an orally bioavailable series containing P1 N-benzylamides.
Burgey CS, Robinson KA, Lyle TA, Nantermet PG, Selnick HG, Isaacs RC, Lewis SD, Lucas BJ, Krueger JA, Singh R, Miller-Stein C, White RB, Wong B, Lyle EA, Stranieri MT, Cook JJ, McMasters DR, Pellicore JM, Pal S, Wallace AA, Clayton FC, Bohn D, Welsh DC, Lynch JJ Jr, Yan Y, Chen Z, Kuo L, Gardell SJ, Shafer JA, Vacca JP. Burgey CS, et al. Among authors: selnick hg. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1353-7. doi: 10.1016/s0960-894x(03)00099-4. Bioorg Med Chem Lett. 2003. PMID: 12657281
Design and synthesis of potent and selective macrocyclic thrombin inhibitors.
Nantermet PG, Barrow JC, Newton CL, Pellicore JM, Young M, Lewis SD, Lucas BJ, Krueger JA, McMasters DR, Yan Y, Kuo LC, Vacca JP, Selnick HG. Nantermet PG, et al. Among authors: selnick hg. Bioorg Med Chem Lett. 2003 Aug 18;13(16):2781-4. doi: 10.1016/s0960-894x(03)00506-7. Bioorg Med Chem Lett. 2003. PMID: 12873514
53 results